key: cord-1021699-s8sx8zmw
authors: Ulhaq, Zulvikar Syambani; Soraya, Gita Vita
title: Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia
date: 2020-07-10
journal: Med Clin (Barc)
DOI: 10.1016/j.medcli.2020.07.002
sha: 7c7767d7fe74b7d0d7486a48a1a16f10f3dbb65b
doc_id: 1021699
cord_uid: s8sx8zmw

nan

J o u r n a l P r e -p r o o f 2 Despite the rapid global increase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, there is currently no effective treatment for patients who have developed severe coronavirus disease 2019 . These severe COVID-19 cases are marked with excess cytokine production and a higher mortality rate. Our previous analysis confirmed that an elevated level of interleukin-6 (IL-6) and C-reactive protein (CRP) are strongly associated with COVID-19 progression [1, 2] . Thus, it is reasonable to suggest that the inhibition of IL-6 signaling cascade may effectively treat patients with severe SARS-CoV-2 infection. Another potential consideration regarding disease progression is the role of IL-6 gene polymorphisms. The two most extensively studied IL-6 gene promoter polymorphisms, -174G/C (rs1800795) and -572C/G (rs1800797), have been shown to affect both the transcription and secretion level of IL-6 [3] . Although the role of such polymorphisms have not been studied among COVID-19 patients specifically, it has been demonstrated in other infectious pneumonias.

In this article, we present a systematic review and meta-analysis on the efficacy of anti-IL-6 receptor (anti-IL-6R) antibody in neutralizing IL-6 by evaluating the reduction of the C-reactive protein (CRP) inflammatory marker, clinical outcomes, and the adverse events among severe COVID-19-infected patients.

Additionally, a meta-analysis was also performed to estimate the association between IL-6 gene polymorphism with predisposition as well as disease severity of pneumonia.

All meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [4] . Records were identified through electronic databases dated up to May 2020 with search terms such as "COVID-19" "SARS-CoV-2", "IL-6", "anti-IL-6R", "Tocilizumab (TCZ), J o u r n a l P r e -p r o o f 3 polymorphism", and "pneumonia" (See Supplementary material). No language restrictions were applied. For TCZ treatment, studies with case-control design evaluating clinical outcomes (i.e., mortality rate, ICU admission, the requirement of mechanical ventilation, and the number of discharged patients) and its adverse events were included. Whereas, for IL-6 gene polymorphisms, studies were included on the basis of the following criteria: (1) aims to evaluate the association between IL-6 gene polymorphisms with predisposition to pneumonia; (2) conducted with a case-control design; and (3) evaluates IL-6 gene polymorphisms in pneumonia patients with or without severe condition (i.e., extra pulmonary bacterial dissemination, sepsis, and multiple organ dysfunction syndrome (MODS)).

Meta-analysis for each gene polymorphism was performed for two or more studies. Genotypic frequency of IL-6 gene polymorphism was tested for deviation from the Hardy-Weinberg equilibrium (HWE) in the control subjects. The associations between IL-6 gene polymorphism with predisposition to pneumonia or severity of pneumonia were calculated by pooled odds ratio (OR) and 95% confidence interval (CI). The Z test was used to evaluate the significance of the pooled effect size. Study heterogeneity was evaluated using Q test and I 2 statistic. A Newcastle-Ottawa scale (NOS) was used to assess the study quality, in which a score ≥ 7 is considered a good study [5] [6] [7] [8] [9] [10] . Table 1 ) with a total sample of n = 66 patients. A large proportion of the samples (89%) were male, with ages ranging from 42 to 73 years old [10] [11] [12] [13] [14] [15] [16] [17] [18] . All patients developed severe COVID-19, marked by acute respiratory distress syndrome (ARDS) during admission, and more than half of studies reported the use of mechanical ventilators. Hypertension was the most common co-morbidity observed in patients with SARS-CoV-2 infection, followed by diabetes mellitus (DM), cerebrovascular disease, cardiovascular disease (CVD), and chronic kidney disease (CKD). Eight of the studies administered TCZ treatment [11] [12] [13] [14] [15] [16] [17] [18] , while one utilized Siltuximab [19] . One to three times injection of anti-IL-6R antibody was mainly given during the onset of ARDS [11, [13] [14] [15] 18] , while the rest were administered several days after the admission/ARDS onset [12, 15, 18, 19] or depending on the level of IL-6 or CRP [17] . Several additional treatments were given in the studies, including antivirals, antibiotics, corticosteroids, anti-malaria (hydroxychloroquine/HCQ), and vasopressors.

The analysis revealed that despite some variability in the levels of CRP posttreatment with anti-IL-6R antibody, peak CRP reduction was observable at 3 to 4days after the administration (Fig. 1) . Additionally, anti-IL-6R antibody treatment also resulted in the suppression of IL-6 levels [12, 16] and remarkable reduction of COVID-19 severity characterized by the improvement of chest CT and its symptoms. initially included [20] [21] [22] [23] [24] ; followed by the exclusion of one study in which the control group displayed milder clinical presentation [24] (Table 2) . No statistical significance was observed between the pooled mortality rates of the TCZ and standard treatment (STD) groups, which may be due to the heterogeneity between studies. However, it can be noted that relative to STD treatment, TCZ treatment was marginally associated Fig. 2B) . In a study conducted by Sciascia et al. [25] , TCZ treatment was shown to increase the likelihood of survival among severe COVID-19 patients ( Table 2) .

This analysis also showed that invasive mechanical ventilation (IMV) was required less in the TCZ group (OR = 0.10, 95%CI 0.01 -0.77, p = 0.03, Fig. 2C ).

No statistical difference was observed in terms of ICU admissions, the number of discharged patients, and the adverse effects of treatment (bacteremia and an elevated level of AST/ALT) between the two groups ( Fig. 2D, E, Supplemental Fig. 1 , respectively). Interestingly, however, Morena et al. [26] demonstrated that 67% of patients administered with TCZ showed an improvement in their clinical severity class. Thus, the administration of TCZ seems beneficial in lowering the mortality rate non-severe cases were examined [29, Supp. Ref. 3, 6] . The characteristics of the included studies are shown in Table 2 . All but four of the studies [30, Supp. Ref.

2,3,5] did not comply with the HWE (p<0.05). Overall, a lack of association between IL-6 -174G/C and -572C/G polymorphisms with pneumonia predisposition was observed in all genetic models ( Table 3) . Additionally, results remained insignificant following subgroup analysis based on ethnicity and age (data not shown).

Interestingly however, we found that IL-6 -174G/C polymorphism was significantly associated with the severity of pneumonia (C vs. G, OR: 1.33, 95%CI 

Interleukin-6 as a potential biomarker of COVID-19 progression

Crucial Laboratory Parameters in COVID-19 Diagnosis and Prognosis: An Updated Meta-Analysis

The association of functional polymorphisms of IL-6 gene promoter with ischemic stroke: analysis in two Chinese populations

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Inflammation-related gene polymorphisms associated with Parkinson's disease: an updated meta-analysis

Associations of Estrogen Receptor Alpha Gene Polymorphisms with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Systematic Review and Meta-Analysis

Estrogen receptor beta (ESR2) gene polymorphism and susceptibility to dementia

Chemokine IL-8 level in aqueous humor of open-angle glaucoma: A meta-analysis

Aqueous humor interleukin-6 levels in primary openangle glaucoma (POAG): A systematic review and meta-analysis

The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/fluid

Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report

First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab

Rapid and Severe Covid-19 Pneumonia with Severe Acute Chest Syndrome in a Sickle Cell Patient Successfully Treated with Tocilizumab

Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab

Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection

Effective treatment os severe COVID-19 patients with tocilizumab

Tocilizumab treatment in COVID-19: A single center experience

Use of tocilizumab for COVID-19 infectioninduced cytokine release syndrome: A cautionary case report

Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. medRxiv

Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care

Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in

gene are associated with severity and outcome of pneumococcal communityacquired pneumonia

Plasma cytokine levels and cytokine gene polymorphisms in Mexican patients during the influenza pandemic A(H1N1)pdm09

Genetic variability in the severity and outcome of community-acquired pneumonia

CRP/IL-6/IL-10 Single-Nucleotide Polymorphisms Correlate with the Susceptibility and Severity of Community-Acquired Pneumonia